#USA #San Diego #oncology research #Tumoroids #Discovery Life Sciences

Discovery Life Sciences Set to Unveil Tumoroids

Discovery Life Sciences, a global leader in biospecimen solutions and specialized lab services, is preparing to launch an innovative product aimed at enhancing oncology research. This groundbreaking introduction, tumoroid cell lines derived from the OncoPro™ culture medium, will be unveiled during the Precision Med Tri-Con 2025, scheduled from March 11 to 13 in San Diego, California.

The tumoroid cell lines represent a transformative tool intended to tackle significant challenges in cancer research. According to McLean Collins, President of Biological Sample Products and Services at Discovery, these cell lines provide a powerful predictive tool that can expedite the identification of life-changing treatments. This release not only highlights Discovery's ongoing commitment to driving innovation in cancer research but also complements their existing offerings in cellular biology, colony-forming cell assays, antibody-drug conjugates, and their expansive portfolio of 10X single cells.

What are Tumoroids?

Tumoroids are 3D multicellular structures derived from cancerous cells sourced from patients, which are grown in a way that mimics the complexity of actual tumors. This approach offers a greater biological relevance compared to traditional 2D cancer models. By utilizing these advanced tumoroids, researchers can achieve more accurate and meaningful results in drug development and diagnostic processes, addressing a critical need in precision medicine.

Highlights from Tri-Con 2025

At Precision Med Tri-Con, Discovery will not only unveil the tumoroid cell lines but also engage in significant scientific presentations led by Dr. Shawn Fahl, Vice President of Laboratory Operations, Cell Services, and R&D for Biological Samples. Key highlights include:

• - A Lunch Presentation: Titled “From Biological Deposits to Scientific Breakthroughs – Accelerating Development through Spatial and Transcriptomic Analyses,” taking place on March 11. This session will focus on the integration of these advanced analytical techniques into cancer research.
• - A Panel Discussion: Covering technological trends in precision medicine, where Dr. Fahl will share insights on emerging innovations that can revolutionize the field, scheduled for March 12.
• - A Poster Presentation: Entitled “Cell-Free DNA and Beyond – A Comprehensive Assessment of Liquid Biopsy Workflows in a Global Clinical Biobank” aimed at enhancing the understanding of liquid biopsies.

Dr. Fahl emphasized, "We are excited to showcase multiple exciting studies at this year’s Precision Med Tri-Con, emphasizing our commitment to advancing precision medicine through cutting-edge technologies and high-quality biospecimens integrated into our workflows. We look forward to engaging with the scientific community and exploring new ways to collectively shape the future of oncology research."

Strategic Innovations

Discovery Life Sciences is heavily investing in cutting-edge technologies, including AI-driven pathology and retrospective clinical biomarker testing workflows. These innovations enable clients to gain actionable quantitative insights from biological samples, significantly enhancing the research landscape.

For more information regarding Discovery Life Sciences and their products, visit www.dls.com.

About Discovery Life Sciences

Discovery Life Sciences is recognized as a leader in providing biospecimens and specialty laboratory services, facilitating the discovery and development of therapies and diagnostics that improve patient outcomes. Their extensive portfolio includes high-quality biospecimens, cell starting materials, and preclinical ADME-tox solutions that accelerate research efforts. Through a comprehensive range of specialized laboratory services in genomics, proteomics, cell biology, and molecular pathology, Discovery Life Sciences delivers essential data and insights for biomarker discovery and clinical trials. For additional details, please visit www.dls.com.